Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Allergan hikes profits forecast despite reform costs By Tracy Staton May 3, 2010 10:23am Allergan (NYSE: AGN) reported better-than-expected first-quarter earnings on strong sales of its Botox anti-wrinkle drug; it slightly raised the low end of its 2010 profit forecast despite costs of U.S. healthcare reforms. Report